Skip to main content

Acute Inflammation

Acute Inflammation: 
def.
 lasts minutes to days and characterized by exudation of fluid and plasma proteins and emigration of leukocytes, predominantly neutrophils.
1. Alterations in vascular caliber that lead to increased blood flow: vasodilation
2. Microvascular structural changes that allow exudation of plasma protens and leukocytes: increased permeability mediated by histamine, bradykinin, leukotrienes, substance P, endothelial retraction
exudate (s.g. > 1.012) vs. transudate (s.g. < 1.012)
3. Emigration of leukocytes: margination, rolling, adhesion, diapedesis, migration
neutrophils predominate (6-24 hours) and replaced by monocytes (24-48 hours)
E-selectin (endothelium) - rolling, adhesion [induced by IL-1 and TNF]
P-selectin (endothelium, platelets) - rolling [present in Weibel-Palade bodies]
L-selectin (leukocytes) - homing
ICAM (interacts with integrins LFA-1 on leukocytes) - adhesion, arrest, transmigration
VCAM (interacts with integrins on eos, monos, lymphs) - adhesion
PECAM-1 (CD31) - platelet-endothelial cell adhesion molecule
Chemotaxis - C5a, LTB4, IL-8
4. Leukocyte activation
Production of arachidonic acid metabolites
Degranulation/Oxidative Burst
Modulation of leukocyte adhesion molecules
5. Phagocytosis
· Recognition and attachment via opsonization (Fc fragment of IgG, C3b, collectins)
· Engulfment via binding of the opsonized particle to the FcgR
· Killing or degradation via
- oxygen-dependent mechanisms using NADPH oxidase, myeloperoxidase (H2O2 + Cl- ®HOCl, destroys bacteria by halogenation)
- oxygen-independent mechanisms (bactericidal permeability increasing protein, lysozyme, lactoferrin, major basic protein, defensins)
After killing acid hydrolases in azurophil granules degrade bacteria within phagolysosomes
Leukocytes can also release products into the extracellular space (lysosomal enzymes, oxygen metabolites, arachadonic acid derivatives) during "regurgitation during feeding" (phagocytic vacuole open to outside transiently), "frustrated phagocytosis" (enzymes released but phagocytosis doesn't occur), "surface phagocytosis" (vacuoles are opened against a resistant surface) or exocytosis. After phagocytosis neutrophils may undergo Mac-1 mediated apoptosis.

One of Four Outcomes to Acute Inflammation:
1. Complete resolution
2. Abscess formation
3. Healing by connective tissue replacement (fibrosis)
4. Progression to chronic inflammation
Chemical Mediators of Inflammation
I.
 Vasoactive amines:
- Histamine (released by mast cell in respomse to physical injury, immune reactions, C3a, C5a, histamine-releasing protein, neuropeptides e.g. substance P, IL-1, IL-8)
- Serotonin (AKA 5-HT) released by platelets (on aggregation) and enterochromaffin cells
II. Plasma Proteases:
- Complement via classic (Ag-Ab mediated) or alternative (endotoxin-mediated) pathway ending in MAC (C5-C9) transmembrane attack complex
- C5a chemotactic factor - C3b and C3bi are opsonins
- controlled by protein inhibitors (C3 and C5 convertases, decay accelerating factor (DAF), factor I (cleaves C3b), C1 inhibitor, CD59)
III. Kinin System
Hageman factor (XII) binds to negatively charged surfaces:
Kininogens -(kallikreins)® kinins (vasoactive peptides) e.g. bradykinin
Kallikrein itself is a potent activatory of Hageman factor leading to autocatalytic activation
IV. Clotting System
Hageman factor (XII) stimulates intrinsic clotting cascade
Factor Xa is where intrinsic and extrinsic cascades converge (­vascular permeability and leukocyte exudation)
Final step is creation of thrombin; (fibrinopeptides also ­vascular permeability and leukocyte exudation)
V. Arachidonic Acid Metabolites
AA is a 20-carbon polyunsaturated fatty acid that occurs as a membrane phospholipid and is released by phospholipase A2
AA is converted by lipoxygenase to LTA4, LTB4, LTC4, LTD4, LTE4
· LTB4 - chomataxis, neutrophil activation and adhesion, neutrophil generation of O2 free radicals and lysosomal enzyne relaese
· LTC4, LTD4, LTE4 - vasoconstriction, bronchospasm, ­ vascular permeability
AA is converted by cyclooxygenase (mediated by COX1 and COX2 genes) to PGG2, PGH2, PGE2, PGD2, PGF2a, PGI2 (prostacyclin) and TXA2 (thromboxane)
· Prostaglandins - pain, fever, vasodilation
· Prostacyclin - vasodilator, platelet aggregation, potentiated permeability and chemotactic effects of other mediators
· Thromboxane - vasoconstrictor, platelet aggregation
Lipoxins are derived from AA via transcellular biosynthetic mechanisms (plt/neut interactions) - proinflammatory and anti-inflammatory actions: inhibit neutrophils but stimulate monocytes.
Aspirin and NSAIDS inhinit cyclooxygenase pathway (PG synthesis).
Glucocorticoids downregulate COX2.
Fish oil has linoleic acid and produces less potent leukotrienes (LTs).
VI. Platelet Activating Factor (PAF)
Derived from IgE-sensitized basophils.
Actions: plt aggregation, vasoconstriction, bronchoconstriction, ­ adhesion, chemotaxis, degranulation and ox burst, ­ synthesis of other mediators (eiconasoids)
VII. Cytokines and Chemokines
Effects are often redundant
Regulate lymphocytes: IL2, IL4, IL10, TGFb
Natural immunity: TNFa, IL1b, IFNa, IFNb, IL6
Activate inflammatory cells: IFNg, TNFa, TNFb, IL5, IL10, IL12
Hematopoiesis: IL3, IL7, c-kit ligand, GCSF, MCSF, GMCSF, stem cell factor
Control of acute phase response: TNFa and IL1
Chemokines: small proteins with paired cysteine residues and disulfide bonds
Function as activators & chemoattractants 
C-X-C or a chemokinesStimulate neutrophilsIL-8
C-C or b chemokinesAttract monos, eos, basos & lymphsMCP1, MIP1a, RANTES
C or g chemokinesLymphocytesLymphotactin
CX3C chemokinesMonos and T cellsFractalkine
VIII. Nitric Oxide
NO is a soluble gas which acts in a paracrine manner to induce cGMP in target cells
Produced by: endothelial cells, macrophages, neurons.
L arginine -(NO synthase, constitutive/induced)® NO
Actions: vasodilation, reduces platelet aggregation and adhesion, reduces leukocyte recruitment.
IX. Lysosomal Constituents of Leukocytes
Neutrophils have two majr types of granules:
azurophil (primary): larger, peroxidase-positive; MPO, lysozyme, defensins, acid hydrolase, neutral proteases (elastase, cathepsin G, proteinase 3, nonspec collagenases). Released into phagolysosome.
specific (secondary): smaller, peroxidase-negative - lysozyme, collagenase, gelatinase, lactoferrin, plasminogen activator, histaminase, alkaline phosphatase. Released extracellularly.
Acid proteases - degrade proteins at an acid pH within phagolysosome
Neutral proteases - degrade proteins extracellularly
Antiproteases - hold them in check, e.g. a1-antitrypsin (inhib neutrophil elastase), a2-macroglobulin 
X. Oxygen-Derived Free Radicals
Superoxide (O2·), Hydrogen peroxide (H2O2), Hydroxyl radical (OH·)
Extracellular release can increases expression of chemokines (IL8), cytokines and endothelial-leukocyte adhesion molecules.
Antioxidants: ceruloplasmin, transferrin, superoxide dismutase, catalase, glutathione peroxidase.
XI. Neuropeptides
Substance P: pain transmission, BP regulation, immune and endocrine cell secretion, increase vascular permeability
Neurokinin A


Defects in Leukocyte Function and Associated Diseases 
Defects in Leukocyte Adhesion

Leukocyte Adhesion Deficiency Type I
Clinical: Impaired leukocyte adhesion and recurrent bacterial infections
Pathophysiology: Defect in integrin b2 chain (shared by LFA-1 and Mac-1): CD18

Leukocyte Adhesion Deficiency Type II
Clinical: Impaired leukocyte adhesion and recurrent bacterial infections (milder than LAD1) 
Pathophysiology: Absence of sialyl-Lewis X, ligand for E-selectin, due to a defect in fucose metabolism 

Defects in Phagocytosis

Chediak-Higashi Syndrome

Defects in Microbicidal Activity
Chronic Granulomatous Disease


Chronic Inflammation: 
def.
 inflammation of prolonged duration (weeks or months) and associated histologically by lymphocytes and macrophages, proliferation of blood vessels, fibrosis and necrosis. Active inflammation, tissue destruction and repair proceeding simultaneously. Occurs in the following settings:
· Persistent infections
· Prolonged exposure to toxic agents (exogenous or endogenous)
· Autoimmunity 

Cells in Chronic Inflammation:
Monocytes: activated by cytokines (IFN-g) secreted by T lymphs, bacterial endotoxins and fibronectin; predominant cell type in 48 hrs. Life span of tissue macrophages is several months.
Lymphocytes, Plasma cells, Mast cells, 
Eosinophils: eotaxin stimulated CCR-3 receptor, granules contain major basic protein (MBP) a cationic protein which is toxic to parasites and epithelial cells.

Granulomatous Inflammation:

def. predominant cell type is the activated macrophage with epithelioid appearance.
Granuloma: def. a focal area of granulomatous inflammation. It consists of a microscopic aggregate of macrophages transformed into epithelium-like cells, surrounded by a collar of lymphocytes and plasma cells. May or may not include giant cells.
Examples: tuberculosis, leprosy, syphilis, cat-scratch disease, foreign-body reaction

Morphologic patterns in acute & chronic inflammation:
· Serous inflammation - marked by effusion (skin blister)
· Fibrinous inflammation - fibrinolysis leads to resolution; conversion to scar called organization.
· Supperative or purulent inflammation - neutrophils, necrotic cells and edema; usually caused by pyogenic bacteria (e.g. staphylococci). An abscess is a focal, localized collection of purulent inflammatory tissue.
· Ulcers - local defect of the surface of a tissue or organ caused by sloughing of inflammatory or necrotic tissue.

Systemic effects of inflammation
· Fever (coordinated by hypothalamus): IL-1, IL-6, TNFa, IFN
· Acute Phase Reaction:
- endocrine & metabolic: C-reactive protein (CRP), serum amyloid A (SAA), serum amyloid P (SAP), complement and coagulation proteins; CRP, SAA and SAP can act as opsonins and fix complement.
- autonomic and behavioral changes: peripheral vasoconstriction and deep vasodilation, rigors, chills, anorexia
· Leukocytosis: leukemoid reactions due to an accelerated release of cells from the bone marrow.
- neutrophilia: most bacterial infections
- lymphocytosis: mononucleosis, mumps, German measles
- eosinophilia: asthma, hay fever, parasitic infections
· Leukopenia: viruses, typhoid fever, rickettsiae, certain protozoa.

Comments

Popular posts from this blog

Regulation of Stroke Volume

Regulation of Stroke Volume The stroke volume is regulated by three variables: the end-diastolic volume (EDV), which is the volume of blood in the ventricles at the end of diastole; the total peripheral resistance, which is the frictional resistance, or impedance to blood flow, in the arteries; and the contractility, or strength, of ventricular contraction. The end-diastolic volume is the amount of blood in the ven- tricles immediately before they begin to contract. This is a work- load imposed on the ventricles prior to contraction, and thus is sometimes called a preload. The stroke volume is directly proportional to the preload; an increase in EDV results in an increase in stroke volume. (This relationship is known as the Frank-Starling law of the heart, discussed shortly.) The stroke volume is also directly proportional to contractility; when the ventricles contract more forcefully,...

Sleep ( physiology )

Sleep Although environmental factors affect sleep, there is evidence that sleep is genetically controlled. This is shown by sleep dis- orders that run in families and the heritability of sleep patterns. Histamine and several other neurotransmitters promote wake- fulness, while adenosine and GABA promote sleep. The neural control of sleep and arousal is discussed in conjunction with the reticular activating system in section 8.4. Two categories of sleep are recognized. Dreams—at least those that are vivid enough to recall upon waking—occur dur- ing rapid eye movement (REM) sleep. The name describes the characteristic eye movements that occur during this stage of sleep. The remainder of the time sleeping is spent in non-REM, or resting, sleep. These two stages of sleep can also be distin- guished by their EEG patterns. The EEG pattern during REM sleep consists of theta waves (5 to 8 cycles per second), although the EEG is often desynchronized as in...

What types of medicines can treat heart failure?

Many different types of medicines help treat heart failure. Some of the more common types are: ACE inhibitors : Widen your blood vessels to lower blood pressure so your heart doesn't have to work as hard, and help your kidneys get rid of extra water Beta-blockers : Slow your heart rate so your heart doesn't have to work as hard, and can help a stiff heart relax so it fills with blood better Diuretics (water pills) : Help your kidneys get rid of the extra water by making you urinate more If you have very bad heart failure that isn’t responding to medicines, doctors may suggest a heart transplant or a mechanical device that helps pump blood.